Astaxanthin / antiOx Cancer Research Results

ASTX, Astaxanthin: Click to Expand ⟱
Features:

Astaxanthin — a lipophilic xanthophyll carotenoid antioxidant (often sourced from Haematococcus pluvialis microalgae and also present in salmon/crustaceans) used as a nutraceutical with prominent redox and inflammation-modulating biology. It is formally classified as a small-molecule dietary carotenoid (natural product / nutraceutical). Common abbreviations include ASTX and AXT. In oncology-context literature it is primarily discussed as a chemopreventive/cytoprotective redox modulator with context-dependent direct antitumor effects, and with theoretical concern for antagonizing ROS-mediated chemo/radiation mechanisms in some settings.
The European Commission considers natural astaxanthin as a food dye

Primary mechanisms (ranked):

  1. NRF2 pathway activation with downstream antioxidant/phase-II enzyme program (context-dependent; often cytoprotective)
  2. Suppression of inflammatory signaling including NF-κB axis with downstream COX-2/iNOS and cytokine modulation
  3. Growth/survival signaling modulation (context-dependent), commonly reported on PI3K–AKT, ERK/MAPK, STAT3
  4. Mitochondria-linked apoptosis induction and cell-cycle perturbation in select tumor models (dose/model-dependent)
  5. Anti-migration/anti-EMT phenotype (e.g., MMPs, cadherin switch; model-dependent)
  6. Ferroptosis/redox-lethal interactions reported in limited models (model-dependent)

Bioavailability / PK relevance: Poor aqueous solubility and variable oral absorption (fat/formulation-dependent). Plasma exposure is typically low with standard oral supplements; engineered formulations (micellar/nanoemulsion) can increase Cmax and shorten Tmax. Reported terminal half-life in healthy volunteers is on the order of ~1–2 days in at least one human PK study.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar astaxanthin concentrations that can exceed typical human plasma levels after supplementation; therefore, mechanistic claims are frequently concentration- and formulation-limited for systemic antitumor translation.

Clinical evidence status: Predominantly preclinical (cell/animal) for direct anticancer claims. Human evidence is stronger for oxidative stress/inflammation biomarker modulation than for anticancer efficacy endpoints; not an approved anticancer drug. Practical oncology use is mainly adjunctive/chemopreventive framing, with caution discussed around concurrent ROS-dependent chemo/radiation.

Astaxanthin is a xanthophyll carotenoid with exceptionally strong antioxidant capacity. In cancer biology, it shows context-dependent effects—largely chemopreventive and cytoprotective, with limited evidence as a direct antineoplastic agent.
Astaxanthin significantly promotes the proliferation of Akkermansia, a microorganism with enhanced anti-tumor immune effects.
Anti-inflammatory signaling, Astaxanthin can inhibit: NF-κB, COX-2, iNOS
Astaxanthin commonly Activates NRF2: Upregulates antioxidant enzymes (GSH, SOD, CAT, GPX)
-Protective in normal tissues
-Potentially tumor-protective in established cancers

Often discouraged during active chemotherapy or radiation
It may:
-Protect tumor cells from ROS-mediated killing
-Reduce lipid peroxidation-based therapies
This concern is similar to:
-Vitamin E
-Trolox
-High-dose carotenoids

Astaxanthin is less likely to be pro-oxidant than lycopene or β-carotene.
Some reports indicate a pro-oxidant effect, but at concentrations that are not achievable for in vito.

Astaxanthin — mechanistic pathway map (cancer-context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NRF2 antioxidant response ↑ NRF2 (context-dependent) → ↓ ROS injury; may blunt ROS-lethal therapies ↑ NRF2 → ↑ GSH/SOD/CAT/GPx; cytoprotection R/G Redox buffering and stress tolerance Often positioned as protective; in established tumors this can be tumor-supportive depending on therapy and redox state.
2 NF-κB inflammatory signaling ↓ NF-κB → ↓ pro-survival inflammation (model-dependent) ↓ inflammatory cytokine signaling R/G Anti-inflammatory microenvironment shift Commonly linked to ↓ COX-2/iNOS and reduced inflammatory tone.
3 PI3K–AKT survival signaling ↓ PI3K/AKT (model-dependent) → ↑ apoptosis, ↓ proliferation ↔ / mild cytoprotective bias (context-dependent) R/G Survival pathway suppression in select tumors Directionality is model- and dose-dependent; some datasets show mixed AKT effects.
4 ERK/MAPK signaling ↓ ERK/MAPK (model-dependent) → ↓ proliferation/EMT ↔ / ↓ stress-activated signaling (context-dependent) R/G Anti-growth signaling modulation Often reported alongside PI3K/AKT changes; may converge on apoptosis/cell-cycle effects.
5 STAT3 axis ↓ STAT3 → ↓ proliferation, ↓ immune-evasion programs (model-dependent) ↔ G Reduced oncogenic transcription signaling Reported in prostate and other models; typically framed as anti-tumor signaling.
6 Mitochondria-mediated apoptosis ↑ intrinsic apoptosis (BAX↑, Bcl-2↓, caspases↑; model-dependent) ↓ stress-induced apoptosis (cytoprotection) R Cell death modulation Key “anti-tumor” readout in many studies; may require higher concentrations than typical systemic exposure.
7 Cell cycle control ↑ p21/p27 and/or arrest signatures (model-dependent) ↔ G Proliferation braking Often co-occurs with apoptosis; direction varies with cell line and dosing.
8 EMT and matrix remodeling ↓ EMT; ↓ MMPs; ↑ E-cadherin (model-dependent) ↔ G Anti-migration / anti-metastatic phenotype Reported via miRNA and cadherin/MMP changes in some colon/breast models.
9 Angiogenesis signaling ↓ VEGF/EGFR signaling (limited, model-dependent) ↔ G Reduced pro-angiogenic drive Less consistently central than NRF2/NF-κB/PI3K–AKT in the literature.
10 Ferroptosis and lipid peroxidation balance ↔ / ↑ ferroptosis (limited models) but also ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation injury R Redox-lethal interaction or protection (context-dependent) Net effect depends strongly on baseline oxidative state and whether therapy relies on lipid peroxidation.
11 Clinical Translation Constraint Low/variable oral exposure; many in-vitro effects are high-concentration. Antioxidant/NRF2 biology raises a plausible antagonism risk for ROS-dependent chemo/radiation (context-dependent). Formulation and dosing strategy strongly influence exposure. — Translational ceiling Best-supported human domain is oxidative stress/inflammation biomarkers rather than anticancer efficacy endpoints.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
antiOx, anti-oxidant activities: Click to Expand ⟱
Source:
Type:
Various antioxidants such as Nrf2, SODs, catalase, GPxs, PRDXs, and GSTs are altered in different cancers and have been linked to prognosis. Their overexpression can correlate with aggressive tumor behavior and resistance to treatment in many contexts.
Scientific Papers found: Click to Expand⟱
5417- ASTX,    Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers
- Study, Nor, NA
*antiOx↑, *BioAv↓, *Dose↝, *BioAv↑,
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,
5422- ASTX,    Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats
- in-vivo, Nor, NA
*antiOx↑, *AntiDiabetic↑, *toxicity∅, *BioAv↓, *BioAv↑,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5425- ASTX,    Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
- in-vivo, AD, NA
*neuroP↑, *antiOx↑, *Inflam↑, *AChE↓, *BACE↓, *MAOA↓, *Aβ↓, *memory↑, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑, *NF-kB↓, *GSK‐3β↓, *ChAT↑, *iNOS↓, *ROS↓, *BBB↑,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF-7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4818- ASTX,  MEL,    Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
TumCD↑, DNAdam↑, *antiOx↑, *AntiTum↑, Inflam↓, tumCV↓, Bcl-2↓, Apoptosis↓, selectivity↑, eff↑, Dose↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
4814- ASTX,    Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review
- Review, Var, NA
Apoptosis↑, EMT↓, AntiCan↑, *cardioP↑, *neuroP↑, TumCG↓, *antiOx↑, *Bacteria↓, *Imm↑, *hepatoP↑, *AntiDiabetic↑, ROS↓, *chemoPv↑,
4813- ASTX,    Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function
- in-vitro, AD, NA
*antiOx↑, *Apoptosis↓, *AntiTum↑, *ROS↓, *MMP↑, *neuroP↑,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,
4806- ASTX,    Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression
- in-vitro, CRC, HCT116
BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, MDA↓, ROS↓, SOD↑, Catalase↑, GPx↑, antiOx↑, TumCG↓, TumCP↓,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 1,   GPx↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 3,   ROS⇅, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Akt↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 6,   BAX↑, 1,   BAX⇅, 1,   Bcl-2↓, 3,   Casp3↑, 2,   cl‑Casp3↑, 1,   TumCD↑, 3,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   GSK‐3β↑, 1,   PI3K↑, 1,   TumCG↓, 3,  

Migration ⓘ

E-cadherin↑, 1,   MMP1↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   TumCMig↓, 3,   TumCP↓, 4,   TumCP↑, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   PSA↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   ChemoSen↑, 3,   ChemoSen⇅, 1,   Dose↓, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 2,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 4,   AntiTum↑, 2,   chemoP↑, 2,   radioP↑, 1,  
Total Targets: 54

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 13,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 3,   SOD↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   iNOS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   GSK‐3β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 2,   IL6↓, 1,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 3,   Inflam↑, 1,   NF-kB↓, 3,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 4,   BioAv↝, 2,   Dose↝, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↓, 1,   AntiDiabetic↑, 2,   AntiTum↑, 2,   cardioP↑, 2,   chemoPv↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 5,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 45

Scientific Paper Hit Count for: antiOx, anti-oxidant activities
16 Astaxanthin
1 Melatonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:382  Target#:1103  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page